- Home
- Equipment
- asia middle east
- cancer specific antigen
Refine by
Locations
- Asia & Middle East
- Afghanistan
- Armenia
- Azerbaijan
- Bahrain
- Bangladesh
- Bhutan
- Brunei Darussalam
- Cambodia
- China
- East Timor
- Georgia
- Guam
- India
- Indonesia
- Iran
- Iraq
- Israel
- Japan
- Jordan
- Kazakhstan
- Kuwait
- Kyrgyzstan
- Laos
- Lebanon
- Malaysia
- Maldives
- Mongolia
- Myanmar
- Nepal
- North Korea
- Oman
- Pakistan
- Palestinian Territories
- Philippines
- Qatar
- Russia
- Saudi Arabia
- Singapore
- South Korea
- Sri Lanka
- Syria
- Taiwan
- Tajikistan
- Thailand
- Turkmenistan
- United Arab Emirates
- Uzbekistan
- Vietnam
- Yemen
Cancer Specific Antigen Equipment Supplied In Asia Middle East
5 equipment items found
by:DEARGEN Inc. based inDaejeon, SOUTH KOREA
ADC (Antibody-drug conjugate) is a next-generation antibody-drug conjugate that has improved efficacy over existing antibodies. This drug combines the advantages of two factors: target specificity, which is a characteristic of an antibody, and cytotoxicity, which is a characteristic of a drug. Specifically, this is a technology focused on targeting and killing ...
Manufactured by:Mol Scientific based in, CHINA
Mol Scientific offer high-quality Tumor-specific antigenic peptide 1 product(MPE0003074). Mol Scientific committed to bring our esteemed customers high quality products and the finest services at highly competitive prices. ...
Manufactured by:Mol Scientific based in, CHINA
Mol Scientific offer high-quality Tumor-specific antigenic peptide 2 product(MPE0005199). Mol Scientific committed to bring our esteemed customers high quality products and the finest services at highly competitive prices. ...
Manufactured by:HEALIOS K.K. based inTokyo, JAPAN
Cancer is the leading cause of death in Japan, with approximately 90% of those deaths said to be caused by solid ...
Manufactured by:Lineage Cell Therapeutics, Inc. based inCarlsbad, CALIFORNIA (USA)
VAC2 is an allogeneic, or non-patient specific, cancer vaccine candidate designed to stimulate patient immune responses to telomerase which is commonly expressed in cancerous cells but not in normal adult cells. VAC2, which is produced from our pluripotent cell technology using a directed differentiation method, is comprised of a population ...